Compare TEVA & HLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEVA | HLN |
|---|---|---|
| Founded | 1901 | 2022 |
| Country | Israel | United Kingdom |
| Employees | 32842 | 24524 |
| Industry | Biotechnology: Pharmaceutical Preparations | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.5B | 41.1B |
| IPO Year | N/A | N/A |
| Metric | TEVA | HLN |
|---|---|---|
| Price | $35.37 | $9.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $38.63 | N/A |
| AVG Volume (30 Days) | 5.3M | ★ 10.5M |
| Earning Date | 04-29-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 1.94% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $6.55 |
| Revenue Next Year | $2.97 | $4.42 |
| P/E Ratio | ★ $28.19 | $49.05 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.99 | $8.65 |
| 52 Week High | $37.35 | $11.28 |
| Indicator | TEVA | HLN |
|---|---|---|
| Relative Strength Index (RSI) | 59.63 | 64.93 |
| Support Level | $30.59 | $9.68 |
| Resistance Level | $35.33 | $10.05 |
| Average True Range (ATR) | 1.13 | 0.14 |
| MACD | 0.20 | 0.09 |
| Stochastic Oscillator | 97.00 | 91.00 |
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.